Literature DB >> 29033014

Clinicopathologic Features of Submucosal Esophageal Squamous Cell Carcinoma.

Manabu Emi1, Jun Hihara2, Yoichi Hamai2, Takaoki Furukawa2, Yuta Ibuki2, Morihito Okada2.   

Abstract

BACKGROUND: The prognoses of submucosal esophageal squamous cell carcinoma patients vary. Patients with favorable prognoses may receive less invasive or nonsurgical interventions, whereas patients with poor prognoses or advanced esophageal cancer may require aggressive treatments. We sought to identify prognostic factors for patients with submucosal esophageal squamous cell carcinoma, focusing on lymph node metastasis and recurrence.
METHODS: We included 137 submucosal esophageal squamous cell carcinoma patients who had undergone transthoracic esophagectomy with systematic extended lymph node dissection. Submucosal tumors were classified as SM1, SM2, and SM3 according to the depth of invasion. Prognostic factors were determined by univariable and multivariable analyses.
RESULTS: Lymph node metastasis was observed in 18.8%, 30.5%, and 50.0% of SM1, SM2, and SM3 cases, respectively. The overall 5-year recurrence rate was 21.9%; the rates for SM1, SM2, and SM3 tumors were 9.4%, 18.6%, and 34.8%, respectively. The SM1 tumors all recurred locoregionally; distant metastasis occurred in SM2 and SM3 cases. The 5-year overall survival rates were 83%, 77%, and 59% for SM1, SM2, and SM3 cases, respectively. On univariable analysis, lymph node metastasis, depth of submucosal invasion (SM3 versus SM1/2), and tumor location (upper thoracic versus mid/lower thoracic) were poor prognostic factors for overall survival. Multivariable Cox regression analyses identified depth of submucosal invasion (hazard ratio 2.51, 95% confidence interval: 1.37 to 4.61) and tumor location (hazard ratio 2.43, 95% confidence interval: 1.18 to 4.63) as preoperative prognostic factors.
CONCLUSIONS: Tumor location (upper thoracic) and infiltration (SM3) are the worse prognostic factors of submucosal esophageal squamous cell carcinoma, but lymph node metastasis is not a predictor of poorer prognosis.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29033014     DOI: 10.1016/j.athoracsur.2017.06.037

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Infiltration Depth is the Most Relevant Risk Factor for Overall Metastases in Early Esophageal Adenocarcinoma.

Authors:  Christina Oetzmann von Sochaczewski; Thomas Haist; Michael Pauthner; Markus Mann; Susanne Braun; Christian Ell; Dietmar Lorenz
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

2.  Failure patterns after adjuvant chemoradiotherapy following endoscopic resection for superficial esophageal squamous cell carcinoma.

Authors:  Toshiki Ikawa; Ryu Ishihara; Koji Konishi; Masahiro Morimoto; Takero Hirata; Naoyuki Kanayama; Sachiko Yamamoto; Noriko Matsuura; Kentaro Wada; Kenji Hayashi; Kazuhiko Ogawa; Teruki Teshima
Journal:  Cancer Med       Date:  2019-06-20       Impact factor: 4.452

3.  CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways.

Authors:  Takayuki Kodama; Yu-Ichiro Koma; Noriaki Arai; Aya Kido; Naoki Urakawa; Mari Nishio; Manabu Shigeoka; Hiroshi Yokozaki
Journal:  Lab Invest       Date:  2020-05-26       Impact factor: 5.662

4.  Comprehensive Analysis of the Expression of TGF-β Signaling Regulators and Prognosis in Human Esophageal Cancer.

Authors:  Wei Song; Wei-Jie Dai; Meng-Hui Zhang; Han Wang; Xiao-Zhong Yang
Journal:  Comput Math Methods Med       Date:  2021-10-23       Impact factor: 2.238

5.  A Retrospective Study of 52 Patients With Primary Small Cell Carcinoma of the Esophagus Treated With Radical Surgery.

Authors:  Ningbo Fan; Zhen Wang; Yuanheng Huang; Zihui Tan; Han Yang; Peng Lin
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.